Group 1 - The core point of the article highlights a decline in the stock price of Aomei Medical, which fell by 5.1% to 12.66 CNY per share, with a trading volume of 281 million CNY and a turnover rate of 4.81%, resulting in a total market capitalization of 8.017 billion CNY [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The revenue composition of Aomei Medical is as follows: surgical and wound care accounts for 79.19%, other categories 6.62%, infection protection 5.05%, advanced dressings 4.68%, and hygiene care 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund is included, and the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which is 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY, showing a year-to-date return of 10.13% and a one-year loss of 1.04% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has been in the position for 2 years and 94 days, with the fund's total asset scale at 6.282 billion CNY, achieving a best return of 103.17% and a worst return of -30.27% during his tenure [3]

Core Insights - The medical device sector experienced a rise of 0.57% on November 12, with Tianyi Medical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Medical Device Sector Performance - Tianyi Medical (301097) closed at 65.30, up 11.34% with a trading volume of 46,500 and a transaction value of 294 million [1] - Jimin Health (603222) closed at 11.33, up 10.00% with a trading volume of 729,500 and a transaction value of 797 million [1] - Zhongyuan Xiehe (600645) closed at 28.61, up 10.00% with a trading volume of 311,400 and a transaction value of 857 million [1] - Other notable gainers include Danah Biotechnology (920009) up 9.99%, Lideman (300289) up 9.89%, and Yipeng Medical (300753) up 8.21% [1] Capital Flow Analysis - The medical device sector saw a net inflow of 739 million from institutional investors, while retail investors experienced a net outflow of 923 million [2][3] - Jimin Health had a net inflow of 205 million from institutional investors, but a net outflow of 138 million from retail investors [3] - Zhongyuan Xiehe also saw a net inflow of 194 million from institutional investors, with a significant net outflow of 932 million from retail investors [3]

Group 1 - The core viewpoint of the news is that Aomei Medical's stock has increased by 5.1%, reaching a price of 13.20 yuan per share, with a trading volume of 268 million yuan and a turnover rate of 4.60%, resulting in a total market capitalization of 8.359 billion yuan [1] - Aomei Medical, established on July 24, 2002, and listed on March 11, 2019, specializes in the research, production, and sales of disposable medical consumables, particularly medical dressings [1] - The main revenue composition of Aomei Medical includes surgical and wound care at 79.19%, other categories at 6.62%, infection protection at 5.05%, advanced dressings at 4.68%, and hygiene care at 4.46% [1] Group 2 - Among the top ten circulating shareholders of Aomei Medical, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top ten shareholders in the third quarter, holding 1.5656 million shares, which accounts for 0.35% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion yuan, showing a year-to-date return of 9.53% and a one-year loss of 1.36% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has a cumulative tenure of 2 years and 92 days, with the fund's total asset scale at 6.282 billion yuan [3]

Core Viewpoint - The company, Aomei Medical Supplies Co., Ltd., held its first meeting of the fourth board of directors on November 11, 2025, where several key resolutions were passed, including the election of the chairman and the establishment of specialized committees. Group 1: Board Meeting Details - The fourth board of directors meeting was held on November 11, 2025, with all 9 directors present [2] - The meeting was chaired by Chairman Cui Jinhai and complied with relevant laws and regulations [2] - Resolutions passed included the election of the chairman and the establishment of specialized committees [3][4] Group 2: Resolutions Passed - The election of the chairman of the fourth board was approved with 9 votes in favor [3][4] - The establishment of specialized committees was approved with 9 votes in favor [3][4] - The appointment of the company president was approved with 9 votes in favor [5][6] - The appointment of the board secretary was approved with 9 votes in favor [8][9] - The appointment of vice presidents was approved with 9 votes in favor [11][12] - The appointment of the financial director was approved with 9 votes in favor [14][15] - The appointment of the securities affairs representative was approved with 9 votes in favor [17][18] - The revision of various committee working rules was approved with 9 votes in favor [19][20][21][22][23][24][25][26][28][29][30][31][32] Group 3: Board Composition - The fourth board consists of 9 directors, including non-independent, employee representative, and independent directors [36][37] - Chairman Cui Jinhai leads the board, which has a term of three years [36][37] Group 4: Management Appointments - The company appointed several key management personnel, including President Cui Jinhai and Secretary Zheng Xiaocheng, with a term of three years [54][55] - Vice presidents include Cheng Hong, Cui Hui, Cui Xingwei, Chen Chunqing, and Huang Tiezhu [54] - The financial director is Huang Tiezhu, and the securities affairs representative is Wang Yuandong [56]

Core Viewpoint - Aomei Medical announced the appointment of several senior management positions during the first meeting of the fourth board of directors, indicating a strategic move to strengthen its leadership team [1] Group 1: Management Appointments - The company appointed Mr. Cui Jinhai as the President, Mr. Zheng Xiaocheng as the Board Secretary, and several Vice Presidents including Ms. Cheng Hong, Mr. Cui Hui, Mr. Cui Xingwei, Ms. Chen Chunqing, and Mr. Huang Tiezhu [1] - Mr. Huang Tiezhu was also appointed as the Chief Financial Officer, while Mr. Wang Yuandong was appointed as the Securities Affairs Representative to assist the Board Secretary [1] Group 2: Financial Performance - For the first half of 2025, Aomei Medical's revenue composition was 94.13% from medical devices and 5.87% from other sources [1] - The company's market capitalization is currently valued at 8 billion yuan [1]

第三条 本工作细则所称薪酬指公司向公司董事、高级管理 人员以货币形式发放的酬金，包括年薪、奖金、津贴及其他福利 待遇。 第四条 本工作细则所称董事是指在公司领取薪酬的董事， 但不包括独立董事；高级管理人员是指公司的总裁、副总裁、财 务总监、董事会秘书和《公司章程》规定的其他人员。 奥美医疗用品股份有限公司 薪酬与考核委员会工作细则 （2025 年 11 月） 第一章 总则 第一条 为进一步建立健全奥美医疗用品股份有限公司（下 称"公司"）董事、高级管理人员的考核和薪酬管理制度，完善 公司治理结构，根据《中华人民共和国公司法》《奥美医疗用品 股份有限公司章程》（下称"《公司章程》"）及其他有关规定， 制定本细则。 第二条 薪酬与考核委员会是董事会按照《公司章程》设立 的专门工作机构，主要负责制定、审查公司董事、高级管理人员 薪酬政策与方案。 第二章 人员组成 — 1 — 第五条 薪酬与考核委员会成员由三名董事组成，其中独立 董事不少于二名。 第六条 薪酬与考核委员会委员由董事长、二分之一以上独 立董事或者全体董事的三分之一以上提名，并由董事会选举产 生。 第七条 薪酬与考核委员会设主任委员（召集人）一名，由 独 ...

奥美医疗用品股份有限公司 战略与可持续发展委员会工作细则 （2025年11月） 第一章 总则 第一条 奥美医疗用品股份有限公司（以下简称"公司"） 为适应战略发展需要，增强公司核心竞争力，确定公司发展规划， 健全投资决策程序，加强决策科学性，提高重大投资决策的效益 和决策的质量，同时为进一步保护公司相关方利益，加强公司履 行可持续发展的能力和意识，实现公司和社会的可持续发展，公 司特设战略与可持续发展委员会，作为负责公司长期发展战略、 重大投资决策和可持续发展事项的专门机构。 第二条 为确保战略与可持续发展委员会规范、高效地开展 工作，公司董事会根据《中华人民共和国公司法》（下称"《公 司法》"）、《奥美医疗用品股份有限公司章程》（下称"《公 司章程》"）等有关规定，特制定本细则。 第二章 人员构成 第三条 战略与可持续发展委员会由三名董事组成。 第四条 战略与可持续发展委员会委员由董事长、二分之一 以上独立董事或者全体董事的三分之一以上提名，并由董事会选 举产生。 — 1 — 第五条 战略与可持续发展委员会设主任委员（召集人）一 名，由公司董事长担任。 战略与可持续发展委员会召集人负责召集和主持战略与可持 ...

奥美医疗用品股份有限公司 董事和高级管理人员持有本公司股份及其变动管理制度 （2025年11月） 第一章 总则 第一条 为加强奥美医疗用品股份有限公司（以下简称"公 司"或"本公司"）对董事和高级管理人员持有及买卖本公司股 票的管理，维护证券市场秩序，根据《中华人民共和国公司法》 （以下简称"公司法"）、《中华人民共和国证券法》（以下简 称"证券法"）、《上市公司董事和高级管理人员所持本公司股 份及其变动管理规则》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等法律、法规及规范性文件以及《奥美医疗用品股份有限 公司章程》（以下简称"公司章程"）的有关规定，并结合本公 司的实际情况，制定本制度。 第二条 本制度适用于公司董事、高级管理人员，公司董事、 高级管理人员应当遵守本制度并履行相关询问和报告义务，其所 持本公司股份是指登记在其名下和利用他人账户持有的所有本公 司股份。从事融资交易融券交易的，还包括记载在其信用账户内 的本公司股份。 2. 新任董事在股东会（或者职工代表大会）通过其任职 事项后两个交易日内； 3. 新任高级管理人员在董事会通过其任职 ...

第一章 总则 第一条 为规范奥美医疗用品股份有限公司（以下称"公司" 或"本公司"）总裁及其他高级管理人员的工作行为，保障公司 高级管理人员依法履行职权，依据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司治理准则》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及其他相关法律、法规、规章、 规范性文件，以及《奥美医疗用品股份有限公司章程》（以下称 "公司章程"）的有关规定，并结合本公司实际，制定本细则。 奥美医疗用品股份有限公司 总裁工作细则 （2025年11月） 第二条 公司日常生产经营实行总裁负责制，设总裁一名， 副总裁若干名，由董事会决定聘任或解聘。 公司高级管理人员包括总裁、副总裁、财务总监、董事会 秘书。 第三条 本细则所称总裁与公司章程所称总裁相对应。总裁 根据董事会的授权，负责公司日常管理和生产指挥，为公司日常 经营管理工作负责人。 第四条 本细则是总裁及其他高级管理人员执行职务过程中 的基本行为准则。总裁及其他高级管理人员履行职权除应遵守本 — 1 — 细则的规定外，还应符合相关法律、法规、规章、规范性文件和 公司章程的规定 ...

奥美医疗用品股份有限公司 提名委员会工作细则 （2025年11月） 第一章 总则 第三条 提名委员会成员由三名董事组成，其中两名为独立 董事。 第四条 提名委员会委员由董事长、二分之一以上独立董事 或者全体董事的三分之一以上提名，并由董事会选举产生。 — 1 — 第五条 提名委员会设主任委员（召集人）一名，由独立董 事委员担任，负责主持委员会工作；主任委员在委员内选举，并 报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致，委员任期届满， 连选可以连任。期间如有委员不再担任公司董事职务，自动失去 委员资格，并由董事会根据上述规定补足委员人数。 第三章 职责权限 第一条 为规范奥美医疗用品股份有限公司（下称"公司" 或"本公司"）高级管理人员的产生，优化董事会组成，完善公 司治理结构，根据《中华人民共和国公司法》《奥美医疗用品股 份有限公司章程》（下称"《公司章程》"）及其他有关规定， 公司特设立董事会提名委员会，并制定本细则。 第二条 董事会提名委员会是董事会按照《公司章程》设立 的专门工作机构，主要负责对公司董事和高级管理人员的人选、 选择标准和程序进行研究并提出建议。 第二章 人员组成 第七条 ...